隶属于 invus public equities advisors llc
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
相关临床试验
61
1 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
1995
进行中（未招募）
1
1.6%
已完成
55
90.2%
终止
4
6.6%
Unknown
1
1.6%
- FDA Advisory Committee meetings remain pivotal regulatory catalysts that can trigger sharp biotech stock swings, as illustrated by Moderna's 9.6% intraday gain following a unanimous positive vote for its influenza vaccine mRNA-1010. - The FDA is not bound by AdCom votes; it has approved drugs despite negative panel recommendations (e.g., Zynquista in 2024) and rejected drugs after positive votes (e.g., Teplizumab in 2021). - The recent Capricor Therapeutics AdCom for deramiocel in Duchenne muscular dystrophy highlighted the need for temporary voting members with specialized disease expertise on advisory panels. - Experts argue FDA should reform AdComs by aggressively recruiting disease-specific specialists, refining conflict-of-interest policies, and asking committees to vote on specific scientific questions rather than a single yes-or-no on approvability.
- Lexicon Pharmaceuticals completed a $94.6 million financing through a public offering and concurrent private placement, pricing 32 million shares at $1.30 per share. - The company plans to use proceeds to fund continued research and development of drug candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders. - Invus L.P., Lexicon's largest stockholder, participated in the private placement through its affiliate, purchasing both common stock and convertible preferred shares. - The financing provides working capital for the biopharmaceutical company's mission to pioneer transformative medicines for patients with unmet medical needs.
- The FDA approved Vertex Pharmaceuticals' Journavx (suzetrigine), the first new class of pain medicine approved in more than 20 years, targeting moderate-to-severe acute pain in adults. - Journavx works by blocking NaV1.8 voltage-gated sodium channels in peripheral nerves to prevent pain signals from reaching the brain, offering a non-addictive alternative to opioids. - Clinical trials in abdominoplasty and bunionectomy patients demonstrated significant pain reduction compared to placebo, with common side effects including itching, muscle spasms, and rash. - The approval addresses a critical unmet need in pain management, as 98% of globally approved pain drugs are generics and the market lacks diversity beyond NSAIDs and opioids.
- Lexicon's SONATA-HCM Phase 3 trial evaluating sotagliflozin for hypertrophic cardiomyopathy is targeting enrollment completion in mid-2026 with topline results expected in Q1 2027. - The company remains on track for Zynquista NDA resubmission in 2026 based on FDA feedback and additional clinical data from the STENO1 study. - Lexicon triggered a $10 million milestone payment from Novo Nordisk for LX9851, an oral ACSL5 inhibitor for obesity, with potential for up to $950 million in remaining milestones. - The company ended 2025 with $125.2 million in cash, sufficient to support planned operations into 2027.
- The SOTA P CARDIA trial demonstrated that sotagliflozin treatment resulted in statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test capacity, and quality of life measures in HFpEF patients without diabetes. - This prospective, randomized, double-blind, placebo-controlled study enrolled 88 participants who were 70 percent female and racially diverse, representing the first clinical evidence of sotagliflozin's benefits specifically in preserved ejection fraction heart failure patients without diabetes. - The findings address a critical unmet need, as more than half of the 6.7 million Americans with heart failure have preserved ejection fraction, a condition with frequent hospitalizations and a 25 percent one-year mortality risk. - Combined with previous data showing reductions in major adverse cardiac events and rehospitalization risks, these results position sotagliflozin as a potentially distinct therapeutic class for heart failure management.
- The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days. - A prespecified meta-analysis combining results from three trials demonstrated significant benefits of early SGLT2 inhibitor initiation, showing reduced risks of cardiovascular death or worsening heart failure and all-cause mortality in the early post-discharge period. - Dapagliflozin was well-tolerated with a safety profile consistent with the SGLT2 inhibitor class, experiencing higher rates of symptomatic hypotension and worsening kidney function but no increase in major hypoglycemia or diabetic ketoacidosis. - Experts at the European Society of Cardiology Congress 2025 endorsed early initiation of SGLT2 inhibitors during heart failure hospitalization based on the totality of evidence supporting their use across the heart failure spectrum.
- Lexicon Pharmaceuticals presented patient survey data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience to inform development of pilavapadin. - The study aims to give voice to nearly 100 million people worldwide suffering from DPNP, which affects approximately 9 million patients in the U.S. and up to 50% of type 2 diabetes patients. - Pilavapadin (LX9211) is an investigational once-daily oral AAK1 inhibitor that demonstrated efficacy in Phase 2a trials and has received FDA Fast Track designation for DPNP treatment.
- DelveInsight's 2025 pipeline analysis reveals a robust heart failure therapeutic landscape with over 70 companies developing 75+ pipeline therapies across various stages of clinical development. - Eli Lilly's tirzepatide demonstrated statistically significant improvements in both primary endpoints for heart failure with preserved ejection fraction and obesity in the Phase 3 SUMMIT trial. - Cytokinetics initiated patient enrollment for the Phase 3 COMET-HF confirmatory trial evaluating omecamtiv mecarbil, a novel cardiac myosin activator for symptomatic heart failure patients. - Leading pipeline candidates include Mesoblast's Rexlemestrocel-L in Phase III trials, Rivus Pharmaceuticals' HU 6 controlled metabolic accelerator, and Heartseed's iPSC-derived cardiomyocyte therapy HS-001.
- Lexicon Pharmaceuticals has launched SONATA-HCM, the only ongoing Phase 3 trial evaluating sotagliflozin in both obstructive and non-obstructive hypertrophic cardiomyopathy, with enrollment active across 20 countries. - The randomized, double-blind study will enroll 500 patients globally and measure improvement in symptoms using the Kansas City Cardiomyopathy Questionnaire, addressing a significant unmet need particularly for non-obstructive HCM patients. - Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor with established efficacy in heart failure, could potentially become the first approved therapy for non-obstructive HCM if trial results support a supplemental new drug application.
- Lexicon Pharmaceuticals' non-opioid painkiller pilavapadin failed to achieve statistical significance versus placebo in Phase IIb RELIEF-DPN-1 trial for diabetic neuropathy pain. - Despite the setback, Lexicon plans to advance the 10mg dose to Phase III development, citing "enormous potential" and significant partner interest in the AAK1 inhibitor program. - The trial results triggered a 50% drop in Lexicon's share price, though analysts note the study design differed from competitors by allowing background pain therapies.
